{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:23:23Z","timestamp":1788942203632,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.euf.2024.03.005","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T21:11:26Z","timestamp":1712437886000},"page":"217-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2046-4246","authenticated-orcid":false,"given":"Ursula M.","family":"Vogl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Testi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.03.005_b0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2024.03.005_b0010","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2024.03.005_b0015","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.03.005_b0020","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.03.005_b0025","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2024.03.005_b0030","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2024.03.005_b0035","article-title":"Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer","volume":"5","author":"Galsky","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.euf.2024.03.005_b0040","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2022.02.019","article-title":"Life-threatening skin reaction with enfortumab vedotin: six cases","volume":"167","author":"Guerrois","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2024.03.005_b0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2024.03.005_b0050","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1200\/JCO.2023.41.6_suppl.508","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy","volume":"41","author":"Sridhar","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692400049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692400049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T12:01:23Z","timestamp":1744545683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545692400049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S240545692400049X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.03.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}